Dataset Information

Strategies to Enhance Logic Modeling-Based Cell Line-Specific Drug Synergy Prediction.

ABSTRACT: Discrete dynamical modeling shows promise in prioritizing drug combinations for screening efforts by reducing the experimental workload inherent to the vast numbers of possible drug combinations. We have investigated approaches to predict combination responses across different cancer cell lines using logic models generated from one generic prior-knowledge network representing 144 nodes covering major cancer signaling pathways. Cell-line specific models were configured to agree with baseline activity data from each unperturbed cell line. Testing against experimental data demonstrated a high number of true positive and true negative predictions, including also cell-specific responses. We demonstrate the possible enhancement of predictive capability of models by curation of literature knowledge further detailing subtle biologically founded signaling mechanisms in the model topology. In silico model analysis pinpointed a subset of network nodes highly influencing model predictions. Our results indicate that the performance of logic models can be improved by focusing on high-influence node protein activity data for model configuration and that these nodes accommodate high information flow in the regulatory network.

SUBMITTER: Niederdorfer B

PROVIDER: S-EPMC7399174 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Strategies to Enhance Logic Modeling-Based Cell Line-Specific Drug Synergy Prediction.

Niederdorfer Barbara B Touré Vasundra V Vazquez Miguel M Thommesen Liv L Kuiper Martin M Lægreid Astrid A Flobak Åsmund Å

Frontiers in physiology 20200728

Discrete dynamical modeling shows promise in prioritizing drug combinations for screening efforts by reducing the experimental workload inherent to the vast numbers of possible drug combinations. We have investigated approaches to predict combination responses across different cancer cell lines using logic models generated from one generic prior-knowledge network representing 144 nodes covering major cancer signaling pathways. Cell-line specific models were configured to agree with baseline acti ...[more]

PMID: 32848834

Similar Datasets

Project description:While synergistic drug combinations are more effective at fighting tumors with complex pathophysiology, preference compensating mechanisms, and drug resistance, the identification of novel synergistic drug combinations, especially complex higher-order combinations, remains challenging due to the size of combination space. Even though certain computational methods have been used to identify synergistic drug combinations in lieu of traditional in vitro and in vivo screening tests, the majority of previously published work has focused on predicting synergistic drug pairs for specific types of cancer and paid little attention to the sophisticated high-order combinations. The main objective of this study is to develop a deep learning-based approach that integrated multi-omics data to predict novel synergistic multi-drug combinations (DeepMDS) in a given cell line. To develop this approach, we firstly created a dataset comprising of gene expression profiles of cancer cell lines, target information of anti-cancer drugs, and drug response against a large variety of cancer cell lines. Based on the principle of a fully connected feed forward Deep Neural Network, the proposed model was constructed using this dataset, which achieved a high performance with a Mean Square Error (MSE) of 2.50 and a Root Mean Squared Error (RMSE) of 1.58 in the regression task, and gave the best classification accuracy of 0.94, an area under the Receiver Operating Characteristic curve (AUC) of 0.97, a sensitivity of 0.95, and a specificity of 0.93. Furthermore, we utilized three breast cancer cell subtypes (MCF-7, MDA-MD-468 and MDA-MB-231) and one lung cancer cell line A549 to validate the predicted results of our model, showing that the predicted top-ranked multi-drug combinations had superior anti-cancer effects to other combinations, particularly those that were widely used in clinical treatment. Our model has the potential to increase the practicality of expanding the drug combinational space and to leverage its capacity to prioritize the most effective multi-drug combinational therapy for precision oncology applications.

Project description:Developing reliable, predictive kinetic models of metabolism is a difficult, yet necessary, priority toward understanding and deliberately altering cellular behavior. Constraint-based modeling has enabled the fields of metabolic engineering and systems biology to make great strides in interrogating cellular metabolism but does not provide sufficient insight into regulation or kinetic limitations of metabolic pathways. Moreover, the growth-optimized assumptions that constraint-based models often rely on do not hold when studying stationary or persistor cell populations. However, developing kinetic models provides many unique challenges, as many of the kinetic parameters and rate laws governing individual enzymes are unknown. Ensemble modeling (EM) was developed to circumnavigate this challenge and effectively sample the large kinetic parameter solution space using consistent experimental datasets. Unfortunately, EM, in its base form, requires long solve times to complete and often leads to unstable kinetic model predictions. Furthermore, these limitations scale prohibitively with increasing model size. As larger metabolic models are developed with increasing genetic information and experimental validation, the demand to incorporate kinetic information increases. Therefore, in this work, we have begun to tackle the challenges of EM by introducing additional steps to the existing method framework specifically through reducing computation time and optimizing parameter sampling. We first reduce the structural complexity of the network by removing dependent species, and second, we sample locally stable parameter sets to reflect realistic biological states of cells. Lastly, we presort the screening data to eliminate the most incorrect predictions in the earliest screening stages, saving further calculations in later stages. Our complementary improvements to this EM framework are easily incorporated into concurrent EM efforts and broaden the application opportunities and accessibility of kinetic modeling across the field.

Dataset Information

Strategies to Enhance Logic Modeling-Based Cell Line-Specific Drug Synergy Prediction.

Publications

Strategies to Enhance Logic Modeling-Based Cell Line-Specific Drug Synergy Prediction.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets